725 filings
Page 2 of 37
CORRESP
cdanzojqqq
24 Jan 24
Correspondence with SEC
12:00am
8-K
jbwv dr40uz
11 Dec 23
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
6:30am
UPLOAD
jxfhe fjjxjm
5 Dec 23
Letter from SEC
12:00am
8-K
fxla6pggo 7ep9
30 Nov 23
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
5:28pm
8-K
mvk8r 5g2zhyejcmmj
9 Nov 23
Aptose Reports Results for the Third Quarter 2023
4:15pm
8-K
y98lx3je8qve4ohjfq
2 Nov 23
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
9:15am
8-K
qvejpdz6xsxla4d19rf
30 Oct 23
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
9:20am
8-K
kn4 k75ue
26 Oct 23
Regulation FD Disclosure
10:12am
8-K
k96hvcbu zmnkj2a2hoz
23 Oct 23
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
8:00am
8-K
8dmgme459siqpj
16 Oct 23
Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference
8:00am
S-8
hyuygti45vup6d jhcg
21 Sep 23
Registration of securities for employees
5:10pm
8-K
bys j6d1vbj
18 Sep 23
Aptose to Present at the Cantor Global Healthcare Conference
8:00am
8-K
mtqftj10398q8
12 Sep 23
Entry into a Material Definitive Agreement
4:30pm
8-K
9m11gkeu59tjkg6kgvv6
6 Sep 23
Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical
8:01am
8-K
yri jsbmy6w4
24 Aug 23
Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
8:00am